David N. Wald

3.8k total citations
83 papers, 2.3k citations indexed

About

David N. Wald is a scholar working on Molecular Biology, Immunology and Hematology. According to data from OpenAlex, David N. Wald has authored 83 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 30 papers in Immunology and 25 papers in Hematology. Recurrent topics in David N. Wald's work include Acute Myeloid Leukemia Research (22 papers), Immune Cell Function and Interaction (19 papers) and CAR-T cell therapy research (16 papers). David N. Wald is often cited by papers focused on Acute Myeloid Leukemia Research (22 papers), Immune Cell Function and Interaction (19 papers) and CAR-T cell therapy research (16 papers). David N. Wald collaborates with scholars based in United States, China and Canada. David N. Wald's co-authors include Xiaoxia Li, George R. Stark, Jinzhong Qin, Kalpana Gupta, Stephen Moreton, Marcos de Lima, Liping Tian, Jennifer E. Towne, John E. Sims and Youcun Qian and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

David N. Wald

74 papers receiving 2.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David N. Wald United States 23 1.2k 907 557 350 318 83 2.3k
Jeehee Youn South Korea 32 1.2k 1.0× 780 0.9× 329 0.6× 203 0.6× 212 0.7× 86 2.5k
Alexandre Corthay Norway 28 2.1k 1.8× 794 0.9× 1.2k 2.2× 237 0.7× 137 0.4× 53 3.2k
Zhixing K. Pan United States 36 1.3k 1.1× 1.6k 1.8× 668 1.2× 742 2.1× 279 0.9× 61 3.3k
Tomoko Hasunuma Japan 30 831 0.7× 873 1.0× 377 0.7× 321 0.9× 122 0.4× 89 2.3k
Stacie A. Dalrymple United States 18 892 0.8× 1.0k 1.1× 579 1.0× 549 1.6× 194 0.6× 24 2.5k
Mazdak Ganjalıkhani-Hakemi Iran 23 731 0.6× 665 0.7× 279 0.5× 305 0.9× 108 0.3× 106 1.8k
Stephan Blüml Austria 30 1.8k 1.5× 1.7k 1.9× 358 0.6× 385 1.1× 184 0.6× 77 3.6k
Luciana Berod Germany 29 2.0k 1.7× 1.0k 1.1× 471 0.8× 388 1.1× 117 0.4× 53 3.2k

Countries citing papers authored by David N. Wald

Since Specialization
Citations

This map shows the geographic impact of David N. Wald's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David N. Wald with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David N. Wald more than expected).

Fields of papers citing papers by David N. Wald

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David N. Wald. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David N. Wald. The network helps show where David N. Wald may publish in the future.

Co-authorship network of co-authors of David N. Wald

This figure shows the co-authorship network connecting the top 25 collaborators of David N. Wald. A scholar is included among the top collaborators of David N. Wald based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David N. Wald. David N. Wald is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Deng, Changchun, Paolo F. Caimi, Umar Farooq, et al.. (2024). Phase I Study Results of UF-Kure19, a CAR-T Product Manufactured in Less Than 1 Day, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma. Blood. 144(Supplement 1). 94–94. 1 indexed citations
2.
Woost, Philip G., Basem M. William, Brenda Cooper, et al.. (2024). Flow cytometry of DNMT1 as a biomarker of hypomethylating therapies. Cytometry Part B Clinical Cytometry. 106(1). 11–24.
3.
Lee, Grace, Kalpana Gupta, Ruifu Liu, et al.. (2023). Loss of GSK3β in hematopoietic stem cells results in normal hematopoiesis in mice. Blood Advances. 7(23). 7185–7189. 1 indexed citations
4.
Hong, Changjin, Yoon Ho Choi, David N. Wald, & Tae Hyun Hwang. (2023). 1199 Identifying a source of dysfunctional CAR T cells incorporating with PBMC scRNA-seq data in patients with Non-Hodgkin Lymphoma. SHILAP Revista de lepidopterología. A1322–A1322. 2 indexed citations
5.
Hong, Changjin, Boro Dropulić, Paolo F. Caimi, et al.. (2022). Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma. Cancer Discovery. 12(8). 1886–1903. 52 indexed citations
6.
Hung, Stevephen, Alina Saiakhova, Zachary Faber, et al.. (2019). Mismatch repair-signature mutations activate gene enhancers across human colorectal cancer epigenomes. eLife. 8. 16 indexed citations
7.
Søraas, Arne, Mieko Matsuyama, Marcos de Lima, et al.. (2019). Epigenetic age is a cell‐intrinsic property in transplanted human hematopoietic cells. Aging Cell. 18(2). e12897–e12897. 35 indexed citations
8.
Ueda, Masumi, Brenda Cooper, Paolo F. Caimi, et al.. (2018). Low-Dose Azacitidine with DNMT1 Level Monitoring to Treat Post-Transplantation Acute Myelogenous Leukemia or Myelodysplastic Syndrome Relapse. Biology of Blood and Marrow Transplantation. 25(6). 1122–1127. 9 indexed citations
9.
Otegbeye, Folashade, et al.. (2018). Inhibiting TGF-beta signaling preserves the function of highly activated, in vitro expanded natural killer cells in AML and colon cancer models. PLoS ONE. 13(1). e0191358–e0191358. 110 indexed citations
10.
Hu, Sophia, Masumi Ueda, Lindsay Stetson, et al.. (2016). A Novel Glycogen Synthase Kinase-3 Inhibitor Optimized for Acute Myeloid Leukemia Differentiation Activity. Molecular Cancer Therapeutics. 15(7). 1485–1494. 35 indexed citations
11.
Karan, Goutam, Amit Chakrabarti, Sukanya Karan, et al.. (2016). Identification of a Small Molecule That Overcomes HdmX-Mediated Suppression of p53. Molecular Cancer Therapeutics. 15(4). 574–582. 17 indexed citations
12.
Wang, Weihuan, Xiaoran Huang, Shuiliang Yu, et al.. (2016). Aberrant Notch Signaling in the Bone Marrow Microenvironment of Acute Lymphoid Leukemia Suppresses Osteoblast-Mediated Support of Hematopoietic Niche Function. Cancer Research. 76(6). 1641–1652. 39 indexed citations
13.
Gupta, Kalpana, Tammy Stefan, James J. Ignatz-Hoover, et al.. (2016). GSK-3 Inhibition Sensitizes Acute Myeloid Leukemia Cells to 1,25D-Mediated Differentiation. Cancer Research. 76(9). 2743–2753. 35 indexed citations
14.
Liu, Na, Hongchun Wang, David N. Wald, et al.. (2014). Wnt signaling is involved in 6-benzylthioinosine-induced AML cell differentiation. BMC Cancer. 14(1). 886–886. 9 indexed citations
15.
Chakrabarti, Amitabha, Kalpana Gupta, Jinbo Yang, et al.. (2012). ATP Depletion Triggers Acute Myeloid Leukemia Differentiation through an ATR/Chk1 Protein-dependent and p53 Protein-independent Pathway. Journal of Biological Chemistry. 287(28). 23635–23643. 11 indexed citations
16.
Gülen, Muhammet F., Katarzyna Bulek, Hui Xiao, et al.. (2012). Inactivation of the Enzyme GSK3α by the Kinase IKKi Promotes AKT-mTOR Signaling Pathway that Mediates Interleukin-1-Induced Th17 Cell Maintenance. Immunity. 37(5). 800–812. 63 indexed citations
17.
Gupta, Kalpana, Amitabha Chakrabarti, Bryan L. Roth, et al.. (2011). Securinine, a Myeloid Differentiation Agent with Therapeutic Potential for AML. PLoS ONE. 6(6). e21203–e21203. 52 indexed citations
18.
Thakur, Vijay S., A.R.M. Ruhul Amin, Rajib Paul, et al.. (2010). p53-Dependent p21-mediated growth arrest pre-empts and protects HCT116 cells from PUMA-mediated apoptosis induced by EGCG. Cancer Letters. 296(2). 225–232. 46 indexed citations
19.
Wald, David N., et al.. (2008). Genetic abnormalities in acute myelogenous leukemia with normal cytogenetics. Current Hematologic Malignancy Reports. 3(2). 83–88. 2 indexed citations
20.
Sandhaus, Linda M., et al.. (2007). Measuring the clinical impact of pathologist reviews of blood and body fluid smears : A laboratory outcome study. Archives of Pathology & Laboratory Medicine. 131(3). 468–472. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeehee Youn Breakdown of academic impact, for papers by Alexandre Corthay Breakdown of academic impact, for papers by Zhixing K. Pan Breakdown of academic impact, for papers by Tomoko Hasunuma Breakdown of academic impact, for papers by Stacie A. Dalrymple Breakdown of academic impact, for papers by Mazdak Ganjalıkhani-Hakemi Breakdown of academic impact, for papers by Stephan Blüml Breakdown of academic impact, for papers by Luciana Berod
Rankless by CCL
2026